Use of common seric tumor markers in patients with solid cancers

Tunisie Medicale

Volumn 86, Issue 6, 2008, Pages 579-583

  Gara, Sonia ^a   Boussen, Hammouda ^a   Ghanem, Abderraouf ^a   Guemira, Fethi ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

AFP; Cancer; CEA; HCG; PSA; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; CA 125 ANTIGEN; MUCIN 1; TUMOR MARKER;

BILIARY TRACT CANCER; BREAST CANCER; CANCER SCREENING; COLORECTAL CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER CARCINOMA; LIVER CELL CARCINOMA; MONITORING; NON SEMINOMATOUS GERMINOMA; OVARY CANCER; PANCREAS CANCER; POSTMENOPAUSE; PROGNOSIS; PROSTATE CANCER; REVIEW; TROPHOBLASTIC TUMOR; BLOOD; BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; LIVER TUMOR; MALE; METABOLISM; NEOPLASM; OVARY TUMOR; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ALPHA-FETOPROTEINS; BREAST NEOPLASMS; CA-125 ANTIGEN; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MUCIN-1; NEOPLASMS; OVARIAN NEOPLASMS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 61949162720     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Regan LS. Screening for hepatocellular carcinoma in high-risk individuals, a clinical review. Arch Intern Med 1989:149: 1741-4
2. Daniele B, Bencivenga A, Megna AS, Tinessa V. alfa-fetoprotein and ultrsonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:[suppl]108-12
3. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, et al. A population-based study on the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-7.
4. Jacobs I, Skates SJ, Macdonald N, et al. screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
5. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systemic review. Br J Obstet Gynaecol 1998;105:1136-47.
6. De Koning HJ, Schroder FH. PSA screening for prostate cancer. Ann Oncol 1998;9:1293-6.
7. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancerbiomarker. Cancer 2004;101:894-904 (Pubitemid 39100420)
8. Duffy MJ. PSA as a marker for prostate cancer. Ann Clin Biochem 1996;33:511-9
9. Bunting PS. Screening for prostate cancer with prostate specific antigen: beware of the biases. Clin Chim Acta 2002;315:71-97 (Pubitemid 33145250)
10. Roddam AW, Duffy MJ, Hamdy FC, Milford Ward A, Patnick J, Price C et al. Use of PSA isoforms for the detection of prostate cancer in men with a PSA level of 2-10ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99
11. Carter HB. Prostate cancers in men with low PSA levels, must we find them? N Engl J Med 2004;350:2292-4.
12. Ford ME, Havstad SL, Demers R, Johnson CC. effect of false positive prostate cancer screening results on subsequent positive cancer screening behaviour. Cancer Epidemiol Biomarkers Prev 2005;14:190-4
13. Prostate specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology 2000;14:267-72.
14. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283-91.
15. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak JW, et al. the effect of digital rectal examination on prostate-specific antigen levels. JAMA 1992;267:2227-8.
16. Carter HB, Pearson JD, Metter EJ, Brant U, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
17. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7
18. Camble AR, Bell JA, Ronan JE, Pearson D, Ellis IO. Use of tumor markers to identify primary site of metastatic cancer.Br Mes J 1993 ;306 :295-8.
19. Savage P. Tumor markers of unknown primary origin: a clinical prespective. Ann Clin Biochemistry 2006;43:1-2.
20. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1996;104:66-73.
21. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
22. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
23. Fowler JE Jr, Platoff GE, Kubrock CA, Stutzman RE. Commercial radioimmunoassay for beta subunit of human chorionic gonadotropin: falsely positive determinations due to elevated serum luteinizing hormone. Cancer 1982;49:136-9.
24. Bosl GJ, Bajorin DF, Sheinfeld J, Motzer RJ, Chaganti RS. Cancer of the testis. In: DeVita VT, Hellman S, Rosenberg SA, et al., ads cancer, principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams* Wilkins,2001:1491-518.
25. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-45.
26. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.Obstet Gynecol1988;72:23-7.
27. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PF, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
28. Steinberg W. The clinical utility of the CA 19 9 tumor associated antigen. AM J Gastroenterol 1990;85:350-5
29. Boussen H, Elmay M, Jerbi G, RAHAL K, Benna F, Mtimet S, Ben ayed F. For a more better use of seric tumor markers. Tun Med 1998;76:1020-1026.
30. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.
31. Bosl GJ, Motzer RJ. Testicular germ cell cancer. N Engl J Med 1977;337:242-51.
32. Gori S, Porrozi S, Roila F, Gatta G, De Giorgi U, Marangolo M. Germ cell tumors of the testis. Crit Rev Oncol Heamatol 2005;53:141-64.
33. Von Eyben FE. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci 2003;40:377-427. (Pubitemid 37204500)
34. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
35. UICC (International Union against Cancer). In: Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss 2002.
36. Huddart RA, Purkalne G. ESMO minimum clinical recommendations for diagnosis, treatment and follow up of mixed or non seminoumatous germ cell tumors (NSGCT). Ann Oncol 2004;16:(Suppl 1):137-9.
37. Lamerz R, Albrecht W, Bialk P, Dati F,Duffy MJ, Gerl A, et al. Tumor markers in germ cell cancers: EGTM recommendations. Anticancer Res 1999;19:2795-8.
38. Pilar Laguna M, Pizzocaro G, Klepp O, Algaba F, Kisbenedek L, Leiva O, et al. EAU guidelines on testicular cancer. Eur Urol 2001;40:102-10.
39. Duffy MJ. CEA as a marker for colorectal cancer. Is it clinically useful. Clin Chem 20001;47:624-30.
40. Sener SF, Imperato SF, Chmiel J, Fremgen A, Sylvester JA. The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA A Cancer J Clin 1989;39:50-6.
41. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Frilsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer. Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
42. Yuen MF, Cheng CC, Lauder U, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinomaincreases the chance of treatment: Hong Kong experience. Hapatology 2000;31:330-5.
43. Diseases and abnormalities of the placenta. In: Cunningham FG, et al. , eds. Williams Obstetrics. 21st ed. New York: McGraw-Hill,2001:835-47.
44. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, et al., eds. Cancer, principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams* Wilkins, 2001:2537-60.
45. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 pt 2):S4-14.
46. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology 1997;11(11A):180-193.
47. Fisher PM, Hancock BW. Gestational trophoblastic disease and their treatment. Cancer Treat Rev 1997;23:1-16. (Pubitemid 27273452)
48. Seki M, Matsui H, Sekiya S. Advances in the clinical laboratory detection of gestational trophoblastic disease. Clin Chim Acta 2004;349:1-13. (Pubitemid 39311983)
49. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000.Int J Gynecol Obstet 2002;77:285-7.
50. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
51. Spencer CA, Lopresti JS, Fatemi S, Nicloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-441.